Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL7382155 | 0.96 | ALDH1A1 (0.38) | ALDH1A1SRD5A2PRMT1 | |
| SCHEMBL16189948 | 0.90 | — | — | |
| SCHEMBL7288250 | 0.86 | ALDH1A1 (0.40) | ALDH1A1PRMT1BRD4BRD2 | |
| SCHEMBL4103157 | 0.84 | ALDH1A1 (0.39) | ALDH1A1PRMT1BRD4BRD2 | |
| SCHEMBL22036847 | 0.82 | CHRM2 (0.38) | ALDH1A1PRMT1BRD4BRD2 | |
| SCHEMBL2436684 | 0.80 | ALDH1A1 (0.37) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31283258 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL24424090 | 0.77 | PRMT1 (0.37) | ALDH1A1SRD5A2PRMT1 | |
| SCHEMBL24203805 | 0.77 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL16189947 | 0.76 | BRD4 (0.41) | ALDH1A1MEN1KMT2ABRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2022013408-A2 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | MERCK SHARP & DOHME CORP. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-5668283-A | Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 1997-09-16 | — | — | US | disclosed |
| US-5606059-A | USEFUL IN THE DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE TYPE DRUGS AND THE ENHANCEMENT OF ALERTNESS | NEUROGEN CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| US-5585490-A | DIANGOSIS AND TREATMENT OF ANXIETY, SLEEP, AND SEIZURE DISORDERS | NEUROGEN CORPORATION (US) | 1996-12-17 | — | — | US | disclosed |
| EP-0738717-A1 | Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines | NEUROGEN CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5367077-A | Certain cycloalkyl and azacycloalkyl pyrrolopyridines; a new class of gaba rain receptor ligands | NEUROGEN CORPORATION (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994025461-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994011374-A1 | CERTAIN ARYL SUBSTITUTED PYRROLOPYRAZINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| US-5286860-A | Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 1994-02-15 | — | — | US | disclosed |
| EP-0552237-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-07-28 | — | — | EP | disclosed |
| US-5216159-A | Preferential antagonists, agonists or inverse agonists for gamma-aminobutyric acid binding sites; anxiolytic agents; anticonvulsants; treatment of sleep disorders | NEUROGEN CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| WO-1992006094-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257371-A1 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | KEAP1, NFE2L2, NQO1 | ALDH1A1 380/4885SRD5A2 1179/4885MEN1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.